Cite
MLA Citation
S. Paprcka et al.. “AB801 is a potent and selective AXL inhibitor that demonstrates significant anti-tumor activity in combination with standard of care therapeutics.” European journal of cancer, vol. 174, n.d., pp. S110–. http://access.bl.uk/ark:/81055/vdc_100168600286.0x00004a